{"id":"W3216009163","doi":"10.1182/blood-2021-154124","title":"A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Minimal residual disease; Medicine; Lymphoblastic Leukemia; Acute lymphocytic leukemia; Leukemia; Internal medicine; Immunology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001584496,0.001330632,0.001684683,0.0003419833,0.0002992506,0.0009919212,0.0009726773,0.001058589,0.002019637],"category_scores_gemma":[0.0007867459,0.0005082023,0.0007255549,0.0003433116,0.0008483483,0.0005789469,0.0002966082,0.003415635,0.0005798491],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007796551,"about_ca_system_score_gemma":0.001345503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001089809,"about_ca_topic_score_gemma":0.00187343,"domain_scores_codex":[0.9995889,0.0002441019,0.00001696201,0.00005036554,0.00003096304,0.00006868952],"domain_scores_gemma":[0.9993696,0.0001214303,0.0000973456,0.00005364637,0.00004171816,0.0003163432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6294477,0.1187641,0.006083595,0.001391248,0.001486524,0.0004904413,0.0004872227,0.003616234,0.1135721,0.000586447,0.004662252,0.1194121],"study_design_scores_gemma":[0.5730848,0.4089367,0.007465593,0.00003843273,0.0004340775,0.0003053956,0.00005914524,0.001491195,0.005686725,0.000163151,0.002316292,0.00001846745],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942681,0.00164902,0.0006274516,0.0004171166,0.0000960458,0.001586176,0.0004347176,0.00007706133,0.0008443941],"genre_scores_gemma":[0.9918606,0.001787342,0.00148739,0.0005544216,0.0001104257,0.001950547,0.001167667,0.00002688662,0.001054776],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002019637,"threshold_uncertainty_score":0.008379757,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02342607894828923,"score_gpt":0.30245612963472,"score_spread":0.2790300506864307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}